Groups suggest changes to FDA’s guidance expanding eligibility criteria for oncology trials
Regulatory NewsJoanne S. Eglovitch
Clinical TrialsNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchClinical TrialsNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy